1. FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA News Release. March 3, 2026.

AI accelerates biopharma from discovery to production, cutting cycle times by up to 40%.

Proteomics-informed, genome-edited CHO design increased productivity up to three-fold and titers two-fold, strengthening CLD for novel biologics and biosimilars. Extended culture robustness was ...

FDA granted Hernexeos accelerated approval for 1st-line HER2-mutant NSCLC after a 44-day review via the National Priority Voucher Program.

FDA expanded zongertinib’s accelerated approval to treatment-naïve HER2-mutant advanced NSCLC, contingent on mutation ...

Novo Nordisk invests €432M ($506M) in Athlone, Ireland to boost oral glucagon-like peptide-1 manufacturing capacity for global markets by 2028.

The February 2026 meeting of the EMA's Committee for Medicinal Products for Human Use (CHMP) resulted in recommendations for twelve new medicines.¹ These outcomes, which included recommendations for ...

Continuing with the rare disease theme (Rare Disease Day is Feb 28), Elisabeth Gardiner of Tevard Biosciences explains in a video interview that research into ultra-rare conditions continues to yield ...

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a ...

Asahi Kasei acquires Aicuris for €780M ($920M), adding anti-infective assets to its transplant and nephrology specialty pharmaceutical platform.

GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...